![]() TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension. ![]() “We also will present two years of follow-up data for TransCon hGH (lonapegsomatropin), our investigational once-weekly growth hormone, which show durable results in children treated for pediatric growth hormone deficiency, and we will provide additional updates on each of our clinical programs in endocrinology.”ĮNDO 2021 Annual Meeting Virtual Event: Presentation Details Oral Presentation ![]() These data demonstrate that TransCon PTH can help to reduce or eliminate standard of care treatment, while maintaining serum calcium within the normal range, improving quality of life and driving expected increases in bone remodeling for people with hypoparathyroidism,” said Mark Bach, M.D., Ph.D., Senior Vice President of Endocrine Medical Sciences at Ascendis Pharma. “We are excited to present the 6-month data from our phase 2 PaTH Forward trial in adult hypoparathyroidism for the first time at a scientific conference. COPENHAGEN, Denmark, Ma(GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced seven presentations at ENDO 2021, the Endocrine Society’s annual meeting, taking place virtually from March 20-23, 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |